FDA-Drug2026-07-29Class IICHEMICAL
Major Pharmaceuticals Levothyroxine Sodium 112 mcg tablets recalled for subpotency
What this means
Major Pharmaceuticals issued a recall of Levothyroxine Sodium 112 mcg tablets (Lot #N02203, expiring 09/2026) because the medication is subpotent—meaning it contains less active ingredient than labeled. Patients taking this lot may not receive the full intended dose of this thyroid replacement medication.
- Check if you have this medication (NDC 0904-6954-61, Lot #N02203).
- Contact your pharmacy or doctor if you have this lot—do not stop taking levothyroxine without medical guidance.
- Your doctor may need to verify your dose or replace your supply.
The agency's original wording
Hazard
Subpotent Drug
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the USA.
Affected count
N/A
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Products
Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6954-61
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0704-2026More Major Pharmaceuticals recalls
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotent drug
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine 25 mcg tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotent drug
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.